Sodium Zirconium Cyclosilicate (Lokelma)
⚡ Sodium zirconium cyclosilicate (SZC) is a highly selective cation exchanger in the gastrointestinal tract.
It is licensed for the management of acute hyperkalaemia.
Always check the BNF here for up-to-date prescribing advice.
ℹ️ About
- 📖 Prescribing advice must be checked in the BNF or local guidelines
- 💊 Brand name: Lokelma
- 🧪 Developed as a safer alternative to sodium polystyrene sulfonate (Resonium)
⚙️ Mode of Action
- 💡 Non-absorbed, inorganic cation-exchange compound
- 🔄 Selectively binds potassium in the gastrointestinal tract → increases faecal excretion
- ⚖️ Minimal absorption → systemic side effects are rare
📋 Indication / Dose
- Used for the treatment of hyperkalaemia (both acute and maintenance)
💊 Dose Range (Always confirm with BNF / datasheet)
| Name | Starting Dose | Frequency | Route |
| Lokelma (initial) | 10 g | 3 times daily, for up to 72 hours | PO |
| Lokelma (maintenance) | 5–10 g | Once daily or alternate days | PO |
🔄 Interactions
- ⚠️ Can reduce absorption of other oral medicines (binds non-selectively) → separate by at least 2 hours before or after
- Particular caution with immunosuppressants (e.g. tacrolimus, ciclosporin)
⚠️ Cautions
- 🌊 Risk of sodium and fluid overload → monitor in patients with heart failure or CKD
- 💧 Caution in patients at risk of oedema
- 🧪 Monitor potassium closely to avoid hypokalaemia
🚫 Contraindications
- ❌ Severe constipation, bowel obstruction or impaction
- ❌ Known hypersensitivity to the drug or excipients
⚡ Side Effects
- 🌊 Fluid retention, peripheral oedema
- ⚖️ Hypokalaemia if overdosed
- 🚽 Gastrointestinal: constipation, mild diarrhoea
📚 References
📝 Revisions
- Content expanded with interactions, cautions, contraindications (Aug 2025)